AUSTIN, Texas--(BUSINESS WIRE)--Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, today announced the completion of a ...
AUSTIN, Texas--(BUSINESS WIRE)--Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, today announced that it was named the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min For years, we've known about how ...
Milestone marks the half-way point of enrollment in pivotal U.S. study designed to support 510(k) submission for the first culture-free, rapid phenotypic ID/AST panel for critically ill pneumonia ...
Pattern Bioscience Inc. reeled in $28.7 million in a series C financing led by Illumina Ventures and Omnimed Capital. The money will be used to complete development of its rapid phenotypic test ...
New funding will be used to accelerate development of first-of-its-kind infectious disease diagnostic platform that will deliver rapid antibiotic treatment guidance Pattern Bioscience, Inc., an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results